Skip to main content

Table 1 Patient demographics and disease characteristics at baseline

From: Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study

Variable NPI (n=74) NIV (n=76) p-value
Age, years
 Median (range) 35 (21.2–51.8) 34 (23.8–57.3) 0.105
Sex, n (%)    0.729
 Male 42 (56.8) 41 (53.9)  
 Female 32 (43.2) 35 (46.1)  
BMI, kg/m2
 Median (range) 25.7 (17.1–41.3) 25.4 (15.6–43.7) 0.256
ECOG performance status, n (%)    0.619
 0 40 (54.1) 38 (50.0)  
 1 34 (45.9) 38 (50.0)  
Sarcoma typesa, n (%)    0.764
 Non-uterine leiomyosarcoma 43 (58.1) 40 (52.6)  
 Liposarcomab 20 (27.0) 22 (28.9)  
 Synovial sarcoma 11 (14.9) 14 (18.4)  
Three major types of liposarcoma    0.078
 Atypical lipoma 9 (12.1) 11 (14.5)  
 Myxoid liposarcoma 10 (13.5) 9 (11.8)  
 Pleomorphic liposarcoma 1 (1.4) 2 (2.6)  
Histological grade, n (%)    0.504
 G1 (well differentiated) 31 (41.9) 37 (48.7)  
 G2 (moderately differentiated) 27 (36.5) 21 (27.6)  
 G3 (poorly differentiated) 16 (21.6) 18 (23.7)  
TMBc status (per Mb), n (%)    0.716
 TMB-High (> 5) 45 (60.8) 44 (57.9)  
 TMB-Low (0–5) 29 (39.2) 32 (42.1)  
Duration of treatment (months)    
 Median (range) 3 (1.5–4.4) 3 (1.6–4.7) 0.317
Number of metastatic sites, n (%)    0.583
 3 12 (16.2) 10 (13.2)  
 > 3 51 (68.9) 58 (76.3)  
 Unknown 11(14.9) 8 (10.5)  
  1. aBased on a central review of pathology; bPrimary liposarcomas were located in the lower extremity (11%), upper extremity (6%), the trunk wall (11%), the retroperitoneum (64%), and the head and neck (8%); cdefined as the number of somatic coding base substitution and indels per megabase of genome. NPI nivolumab plus ipilimumab, NIV nivolumab, BMI body mass index, ECOG Eastern Collaborative Oncology Group, TMB tumour mutation burden